Usage of C-reactive protein testing in the diagnosis and monitoring of psoriatic arthritis (PsA): results from a real-world survey in the USA and Europe by Ogdie, A, Tillett, W, Booth, N, Howell, O, Schubert, A, Peterson, S, Chakravarty, SD, Coates, LC

Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase... by Coates, LC, Rahman, P, Mease, PJ, Shawi, M, Rampakakis, E, Kollmeier, AP, Xu, XL, Chakravarty, SD, McInnes, IB, Tam, L-S

Modulation of interleukin-23 signaling with guselkumab in biologic-naive patients versus tumor necrosis factor inhibitor–inadequate responders with active psoriatic arthritis by Siebert, S, Coates, LC, Schett, G, Raychaudhuri, SP, Chen, W, Gao, S, Seridi, L, Chakravarty, SD, Shawi, M, Lavie, F, Sharaf, M, Zimmermann, M, Kollmeier, AP, Xu, XL, Rahman, P, Mease, PJ, Deodhar, A

Modulation of Interleukin‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis by Siebert, S, Coates, LC, Schett, G, Raychaudhuri, SP, Chen, W, Gao, S, Seridi, L, Chakravarty, SD, Shawi, M, Lavie, F, Sharaf, M, Zimmermann, M, Kollmeier, AP, Xu, XL, Rahman, P, Mease, PJ, Deodhar, A